消化器内科の世界市場

消化器内科の世界市場は2030年までに457億米ドルに達する見込み

2024年に341億米ドルと推定される消化器内科の世界市場は、2024～2030年の分析期間においてCAGR 5.0%で成長し、2030年には457億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである生物製剤／バイオシミラーは、CAGR 3.8％を記録し、分析期間終了時には113億米ドルに達すると予測されます。制酸剤セグメントの成長率は、分析期間中CAGR 4.8%と推定されます。

米国市場は93億米ドルと推定、中国はCAGR 7.7％で成長予測

米国の消化器内科市場は2024年に93億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに89億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と4.9％と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界の消化器内科市場- 主要動向と促進要因のまとめ

消化器内科が現代医療で注目される理由とは？

消化器内科は、消化器系とその疾患に焦点を当てた医学の一分野であり、消化器系疾患の世界の有病率の上昇により、現代ヘルスケアにおいてますます重要な分野となっています。過敏性腸症候群（IBS）、胃食道逆流症（GERD）、クローン病や潰瘍性大腸炎などの炎症性腸疾患（IBD）、非アルコール性脂肪性肝疾患（NAFLD）などの肝疾患の罹患率の増加が、消化器内科における専門的治療の需要を押し上げています。人口の高齢化、食習慣の変化、消化器の健康に対する意識の高まり、肥満や糖尿病などの疾患の世界の増加といった要因が、消化器疾患の負担増に寄与しています。さらに、環境要因や遺伝的要因が消化器疾患の主な原因であると認識されるようになってきており、消化器内科はこれらの疾患の病因と治療の両方を理解する上で、より適切なものとなってきています。その結果、消化器内科は予防ヘルスケアに欠かせないものとなり、早期診断と早期管理は患者の予後を改善する上で極めて重要となっています。診断、治療、そして個別化医療への関心の高まりが、消化器内科を現代医療におけるエキサイティングで急速に進化する分野にしており、増え続ける世界の健康課題に対処するために、この分野に注目する医療従事者や研究者が増えています。

技術の進歩は消化器内科の実践をどのように変えているのか？

技術の進歩は消化器内科の分野を劇的に変化させ、診断精度と治療効果の両方を大幅に改善しました。画像診断では、高精細内視鏡、カプセル内視鏡、共焦点レーザー内視鏡（CLE）の開発により、消化管の異常を早期に発見する能力が向上しました。例えば、カプセル内視鏡検査では、消化管全体、特に従来評価が困難であった小腸を非侵襲的に可視化することができます。さらに、バイオマーカーと分子検査の進歩により、より正確な診断と個別化された治療計画が可能になりつつあります。特に大腸がんの場合、遺伝子検査が危険因子の特定と治療の個別化に役立ちます。人工知能（AI）は、特に内視鏡画像や患者データの解析において、人間が発見することが困難なパターンを特定するために、消化器内科で果たす役割も大きくなってきています。AIアルゴリズムは、画像や検査結果の微妙な変化を特定することで、消化器がんや炎症性疾患などの早期発見を支援することができます。さらに、内視鏡的超音波（EUS）や内視鏡的逆行性胆管膵管造影（ERCP）などの低侵襲技術の使用により、従来の外科的方法と比較して、患者の回復時間や合併症のリスクが大幅に減少しています。こうした技術革新は、患者の転帰を改善し、治療の精度を高め、消化管疾患の早期発見とより効果的な管理を可能にしています。

消化器内科市場の成長を促進する主な要因は？

消化器内科市場は、高齢化、ライフスタイルの変化、胃腸の健康に対する意識の高まりなど、いくつかの促進要因により大きな成長を遂げています。世界人口の高齢化に伴い、大腸がん、肝臓疾患、機能性胃腸障害など、高齢者に多い胃腸疾患の発生率が高くなっています。さらに、食生活の乱れ、運動不足、高いストレスレベルなどの生活習慣が、肥満、GERD、IBDなどの疾患の増加につながっています。NAFLDや胃食道逆流症などの疾患と密接に関連する肥満の有病率の上昇は、特に先進諸国において世界の健康危機となりつつあります。ライフスタイルと胃腸の健康との関連性に対する認識が高まるにつれ、予防医療、定期的な検診、消化器疾患の治療を求める人が増えています。大腸がんやC型肝炎などの疾患に対する世界の意識の高まりも、消化器内科サービスに対する需要の増加に寄与しています。特に大腸がんの検診プログラムの開発は、発見率の向上と治療成績の改善につながり、消化器内科市場の成長をさらに促進しています。また、新興国ではヘルスケアへのアクセスが向上しているため、消化器内科サービスの利用範囲が拡大しています。専門的な消化器内科センターが拡大し、高度な診断と治療が利用可能になりつつあることは、消化器疾患の世界の負担増に対処する一助となっています。

消化器内科市場成長の主な促進要因は？

消化器内科市場の成長は、テクノロジーの進歩、疾患有病率の増加、患者中心のケアへの注力など、いくつかの要因によってもたらされます。特にIBD、大腸がん、NAFLDのような疾患は、食生活の乱れ、喫煙、座りっぱなしのライフスタイルといった現代的なライフスタイル要因によってより一般的になっています。これらの疾患が蔓延するにつれ、これらの疾患を管理するための専門医、診断、治療に対する需要が高まっています。さらに、AI支援内視鏡や低侵襲手術など、診断や治療における技術革新は、消化器内科処置に関連する精度、スピード、患者の転帰を向上させています。消化器内科へのゲノミクスの統合も、個別化医療や消化器疾患の標的治療への移行に伴い、成長を後押ししています。予防医療への注目が高まっていることも大きな促進要因です。大腸がん、肝炎、その他の消化器疾患の検診へのアクセスが改善されたことで、ヘルスケアシステムはこれらの疾患をより早い段階で発見することができ、より効果的な治療と生存率の向上につながります。さらに、新興市場における中間層の拡大が消化器内科サービスの世界的成長に寄与しています。公衆衛生キャンペーン、政府の取り組み、消化器疾患に対する認識を高める国際的な取り組みが、消化器内科サービスの需要をさらに高めています。最後に、腸内細菌叢とその胃腸の健康と全体的な健康における役割に対する関心の高まりが、新たな調査と治療法の選択肢を生み出し、消化器内科を医療イノベーションの最前線に位置づけています。これらの要因が相まって、消化器内科市場の拡大が促進され、世界中の消化器疾患患者のケアの質が向上しています。

セグメント

薬剤タイプ（生物製剤／バイオシミラー、制酸剤、緩下剤、止瀉剤、制吐剤、抗潰瘍剤、その他の薬剤タイプ）、疾患タイプ（炎症性腸疾患、クローン病、潰瘍性大腸炎、過敏性腸症候群、胃食道逆流症、肝臓疾患、大腸がん、その他の疾患タイプ）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の41社）

• AbbVie Inc.
• Abbott Laboratories
• AstraZeneca plc
• Bayer AG
• Bausch Health Companies Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Cipla Ltd.
• Ferring Pharmaceuticals
• GI Alliance
• GlaxoSmithKline plc
• Johnson & Johnson
• Medtronic plc
• Novartis AG
• Olympus Corporation
• Pfizer Inc.
• Salix Pharmaceuticals
• Sanofi S.A.
• Sebela Pharmaceuticals
• Takeda Pharmaceutical Company

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Gastroenterology Market to Reach US$45.7 Billion by 2030

The global market for Gastroenterology estimated at US$34.1 Billion in the year 2024, is expected to reach US$45.7 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Biologics / Biosimilars, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$11.3 Billion by the end of the analysis period. Growth in the Antacids segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.3 Billion While China is Forecast to Grow at 7.7% CAGR

The Gastroenterology market in the U.S. is estimated at US$9.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.9 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Gastroenterology Market - Key Trends & Drivers Summarized

Why Is Gastroenterology Becoming a Key Focus in Modern Medicine?

Gastroenterology, the branch of medicine focused on the digestive system and its disorders, has become an increasingly critical field in modern healthcare due to the rising prevalence of digestive diseases globally. The growing incidence of conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis, and liver diseases like non-alcoholic fatty liver disease (NAFLD) is propelling the demand for specialized care in gastroenterology. Factors such as aging populations, changes in dietary habits, increased awareness of digestive health, and the global rise in conditions like obesity and diabetes contribute to the growing burden of gastrointestinal disorders. Additionally, environmental and genetic factors are increasingly being recognized as major contributors to gastrointestinal diseases, making gastroenterology more relevant in understanding both the etiology and treatment of these conditions. As a result, gastroenterology has become an essential part of preventive healthcare, with early diagnosis and management being crucial for improving patient outcomes. Advances in diagnostics, treatments, and a growing emphasis on personalized medicine are making gastroenterology an exciting and rapidly evolving area of modern healthcare, with an increasing number of healthcare providers and researchers focusing on this field to address the growing global health challenge.

How Are Technological Advancements Transforming Gastroenterology Practices?

Technological advancements have dramatically transformed the field of gastroenterology, significantly improving both diagnostic accuracy and treatment effectiveness. In diagnostic imaging, the development of high-definition endoscopy, capsule endoscopy, and confocal laser endomicroscopy (CLE) has enhanced the ability to detect gastrointestinal abnormalities at earlier stages. For instance, capsule endoscopy allows for the non-invasive visualization of the entire gastrointestinal tract, particularly the small intestine, a traditionally difficult area to assess. Additionally, advancements in biomarkers and molecular testing are allowing for more accurate diagnosis and personalized treatment plans, particularly in the case of colorectal cancer, where genetic testing can help identify risk factors and tailor therapies. Artificial intelligence (AI) is also playing a growing role in gastroenterology, particularly in the analysis of endoscopic images and patient data to identify patterns that may be difficult for human practitioners to detect. AI algorithms can assist in early detection of gastrointestinal cancers, inflammatory diseases, and other conditions by identifying subtle changes in imaging and laboratory results. Furthermore, the use of minimally invasive techniques, such as endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP), has significantly reduced patient recovery time and risk of complications compared to traditional surgical methods. These technological innovations are improving patient outcomes, enhancing treatment precision, and enabling earlier detection and more effective management of gastrointestinal disorders.

What Are the Key Factors Driving Growth in the Gastroenterology Market?

The gastroenterology market is experiencing significant growth due to several driving factors, including an aging population, lifestyle changes, and increasing awareness of gastrointestinal health. As the global population ages, there is a higher incidence of gastrointestinal diseases such as colorectal cancer, liver diseases, and functional gastrointestinal disorders, which are more common in older adults. Additionally, lifestyle factors such as poor diet, lack of exercise, and high stress levels have contributed to an increase in conditions like obesity, GERD, and IBD. The rising prevalence of obesity, which is closely linked to conditions like NAFLD and gastroesophageal reflux disease, is becoming a global health crisis, particularly in developed countries. As awareness of the connection between lifestyle and gastrointestinal health grows, more people are seeking preventive care, regular screenings, and treatments for digestive disorders. The rise in global awareness of conditions like colorectal cancer and hepatitis C has also contributed to the increasing demand for gastroenterology services. The development of screening programs, particularly for colorectal cancer, has led to higher detection rates and better outcomes, further driving the growth of the gastroenterology market. Additionally, increasing access to healthcare in emerging economies is expanding the reach of gastroenterology services, where rising middle-class populations are demanding better care for digestive disorders. The expansion of specialized gastroenterology centers and the growing availability of advanced diagnostics and treatments are helping to address the growing global burden of digestive diseases.

What Are the Primary Drivers Behind the Growth of the Gastroenterology Market?

The growth of the gastroenterology market is driven by several factors that combine advancements in technology, increasing disease prevalence, and a focus on patient-centered care. A key driver is the rising global prevalence of gastrointestinal diseases, particularly conditions like IBD, colorectal cancer, and NAFLD, which are more common due to modern lifestyle factors such as poor diets, smoking, and sedentary lifestyles. As these diseases become more prevalent, there is a greater demand for gastroenterology specialists, diagnostics, and treatments to manage these conditions. Additionally, technological innovations in diagnostics and treatments, such as AI-assisted endoscopy and minimally invasive surgeries, are improving the accuracy, speed, and patient outcomes associated with gastroenterology procedures. The integration of genomics into gastroenterology is also driving growth, as the field moves toward personalized medicine and targeted therapies for gastrointestinal diseases. The increasing focus on preventive care is another significant growth driver. With improved access to screenings for colorectal cancer, hepatitis, and other gastrointestinal diseases, healthcare systems can catch these conditions at earlier stages, leading to more effective treatment and improved survival rates. Moreover, the expanding middle class in emerging markets is contributing to the global growth of gastroenterology services, as more people seek specialized care for digestive disorders. Public health campaigns, government initiatives, and international efforts to raise awareness of gastrointestinal diseases are further fueling the demand for gastroenterology services. Finally, the growing interest in gut microbiota and its role in gastrointestinal health and overall well-being is sparking new research and treatment options, positioning gastroenterology at the forefront of medical innovation. Together, these factors are driving the expansion of the gastroenterology market and enhancing the quality of care for patients with digestive diseases worldwide.

SCOPE OF STUDY:

The report analyzes the Gastroenterology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents, Other Drug Types); Disease Type (Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• Abbott Laboratories
• AstraZeneca plc
• Bayer AG
• Bausch Health Companies Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Cipla Ltd.
• Ferring Pharmaceuticals
• GI Alliance
• GlaxoSmithKline plc
• Johnson & Johnson
• Medtronic plc
• Novartis AG
• Olympus Corporation
• Pfizer Inc.
• Salix Pharmaceuticals
• Sanofi S.A.
• Sebela Pharmaceuticals
• Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Gastroenterology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Gastrointestinal Disorders Drives Demand for Gastroenterology Services and Treatments
  • Here's the Story: How Advancements in Endoscopic Technology Are Revolutionizing Gastroenterology Diagnostics
  • Rising Awareness of Digestive Health and Wellness Fuels Growth in Preventive and Diagnostic Gastroenterology Services
  • Technological Innovations in Minimally Invasive Procedures Expand Treatment Options for Gastrointestinal Disorders
  • Surge in Aging Populations Globally Increases the Need for Gastroenterology Care and Disease Management
  • Here's How the Growing Focus on Personalized Medicine is Shaping the Future of Gastroenterology Treatments
  • Rising Incidence of Inflammatory Bowel Diseases (IBD) and Celiac Disease Strengthens the Business Case for Specialized Care
  • Expanding Role of Telemedicine and Remote Monitoring Drives Access to Gastroenterology Services in Underserved Areas
  • Increasing Research and Clinical Trials in Microbiome and Gut Health Create New Opportunities for Therapeutic Advancements
  • Here's How Advances in Artificial Intelligence and Machine Learning are Revolutionizing Gastroenterology Diagnostics
  • Growing Demand for Targeted Therapies and Biologics in Treating Gastrointestinal Disorders Expands Treatment Options
  • Global Increase in Obesity and Lifestyle-Related Disorders Drives Growth in Gastroenterology-Based Disease Prevention
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gastroenterology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Biologics / Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Biologics / Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Biologics / Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Laxatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antidiarrheal Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antidiarrheal Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Antidiarrheal Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Antiemetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Antiulcer Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Antiulcer Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Antiulcer Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Irritable Bowel Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Irritable Bowel Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Gastroesophageal Reflux Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Gastroesophageal Reflux Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Inflammatory Bowel Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Crohn's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 59: USA Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 86: China Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Gastroenterology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 107: France Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 134: UK Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 137: UK Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Spain 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 146: Spain Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Spain Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Spain 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Russia 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 155: Russia Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Russia Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Russia 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 158: Russia Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Russia Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Russia 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Europe Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Europe 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Europe Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Rest of Europe 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Europe Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Rest of Europe 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Gastroenterology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Asia-Pacific Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Asia-Pacific 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Asia-Pacific Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Asia-Pacific 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Asia-Pacific Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Asia-Pacific 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 182: Australia Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Australia Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Australia 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 185: Australia Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Australia Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Australia 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 188: Australia Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Australia Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Australia 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 191: India Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: India Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: India 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 194: India Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: India Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: India 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 197: India Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: India Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: India 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 200: South Korea Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: South Korea Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: South Korea 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 203: South Korea Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: South Korea Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: South Korea 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 206: South Korea Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: South Korea Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: South Korea 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Asia-Pacific Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Asia-Pacific Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 215: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Rest of Asia-Pacific Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Rest of Asia-Pacific 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Gastroenterology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 221: Latin America Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Latin America Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Latin America 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 224: Latin America Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Latin America Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Latin America 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 227: Latin America Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Latin America Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Latin America 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 230: Argentina Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Argentina Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Argentina 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 233: Argentina Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Argentina Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Argentina 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 236: Argentina Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Argentina Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Argentina 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 239: Brazil Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Brazil Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Brazil 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 242: Brazil Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Brazil Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Brazil 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 245: Brazil Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Brazil Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Brazil 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 248: Mexico Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Mexico Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Mexico 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 251: Mexico Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Mexico Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Mexico 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 254: Mexico Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Mexico Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Mexico 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Latin America Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Latin America 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Latin America Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Latin America 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Latin America Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Latin America Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Latin America 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Gastroenterology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 269: Middle East Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Middle East Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Middle East 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 272: Middle East Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Middle East Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Middle East 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 275: Middle East Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Middle East Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Middle East 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 278: Iran Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Iran Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Iran 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 281: Iran Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Iran Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Iran 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 284: Iran Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Iran Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Iran 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 287: Israel Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Israel Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Israel 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 290: Israel Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Israel Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Israel 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 293: Israel Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Israel Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Israel 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Saudi Arabia Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Saudi Arabia 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Saudi Arabia Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Saudi Arabia 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 302: Saudi Arabia Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Saudi Arabia Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Saudi Arabia 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 305: UAE Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: UAE Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: UAE 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 308: UAE Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: UAE Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: UAE 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 311: UAE Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: UAE Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: UAE 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Middle East Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Middle East 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Middle East Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Middle East 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Middle East Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Middle East Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Middle East 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 323: Africa Recent Past, Current & Future Analysis for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Africa Historic Review for Gastroenterology by Drug Type - Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Africa 15-Year Perspective for Gastroenterology by Drug Type - Percentage Breakdown of Value Sales for Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 326: Africa Recent Past, Current & Future Analysis for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Africa Historic Review for Gastroenterology by Disease Type - Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Africa 15-Year Perspective for Gastroenterology by Disease Type - Percentage Breakdown of Value Sales for Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types, Inflammatory Bowel Diseases and Crohn's Disease for the Years 2015, 2025 & 2030
  • TABLE 329: Africa Recent Past, Current & Future Analysis for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Africa Historic Review for Gastroenterology by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Africa 15-Year Perspective for Gastroenterology by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION